Strategy Inc. <MSTR.O>: Barclays cuts target price to $125 from $130
MSTR•Related News

Opus Genetics completes enrollment in Phase 3 trial of OPGx-LCA5 gene therapy for LCA5 retinal disease
IRD•

Marriott raises annual room revenue growth forecast
MAR•

CIBC restates Q2 2026 financial results after Final Terms omission error
CM•

BrightSpring Health Services Inc <BTSG.O>: Raymond James cuts target price to $75 from $80
BTSG•

Twist Bioscience posts fiscal Q3 2026 earnings report and investor presentation online
TWST•